Le Lézard
Classified in: Health, Science and technology, Covid-19 virus

Can a statin maintain the health of adults 75 and older?

SAN ANTONIO, Nov. 27, 2020 /PRNewswire-PRWeb/ -- UT Health San Antonio's Sam and Ann Barshop Institute for Longevity and Aging Studies announced Nov. 27 that enrollment is open for a new clinical trial called PREVENTABLE. The study will investigate whether taking atorvastatin, a drug commonly used to lower cholesterol also called Lipitor®, can help adults age 75 and older maintain health by preventing dementia, disability and heart disease.

The study, which aims to be one of the largest ever conducted in older adults, will include more than 20,000 participants across the U.S., including 450 from San Antonio. The study will randomize participants without heart disease or dementia to receive either atorvastatin or placebo. The placebo looks like the study drug but has no medicine in it. Researchers will follow participants for up to five years and test their memory, thinking and physical abilities, and monitor them for events such as heart attacks or strokes.

Study participation will be easy and efficient. Researchers will follow participants using electronic health records and Medicare data, and with study visits over the telephone. Study drug will be shipped directly to participants' homes every three months.

The Barshop Institute at UT Health San Antonio is one of the first PREVENTABLE study sites to be activated, said principal investigator Nicolas Musi, MD, institute director and professor of medicine in the university's Joe R. and Teresa Lozano Long School of Medicine.

"We really don't know how these drugs work in older adults," Dr. Musi said. "Most, if not all, of the studies of statins have been done in much younger people, in their 50s and 60s, but studies in adults over 75 are rare."

About one in three people in the U.S. over the age of 75 without heart disease are taking statins. In addition to learning whether statins can prolong health in older adults, the PREVENTABLE study will help clarify which older adults should not be taking statins.

"Participants don't have to have a history of high cholesterol," Dr. Musi, an endocrinologist, said. "This study is conducted to see if this medicine, regardless of cholesterol level, is able to improve cognition and brain function, prevent dementia, improve physical function, and prevent cardiovascular disease and strokes."

"Persons with a history of heart disease, stroke or dementia are not eligible for the study, but people with diabetes are eligible," Dr. Musi said. "So are patients with mild cognitive impairment."

The National Institutes of Health, which is funding the study, is interested in San Antonio as a center of minority participant recruitment. "The PREVENTABLE study is not exclusively for the Hispanic population, but this group is of special interest to us," Dr. Musi said.

Interested people may call the Barshop Institute clinical research line at (210) 450-0020.

# # #

The Long School of Medicine at The University of Texas Health Science Center at San Antonio is named for Texas philanthropists Joe R. and Teresa Lozano Long. The school is the largest educator of physicians in South Texas, many of whom remain in San Antonio and the region to practice medicine. The school teaches more than 900 students and trains 800 residents each year. As a beacon of multicultural sensitivity, the school annually exceeds the national medical school average of Hispanic students enrolled. The school's clinical practice is the largest multidisciplinary medical group in South Texas with 850 physicians in more than 100 specialties. The school has a highly productive research enterprise where world leaders in Alzheimer's disease, diabetes, cancer, aging, heart disease, kidney disease and many other fields are translating molecular discoveries into new therapies. The Long School of Medicine is home to a National Cancer Institute-designated cancer center known for prolific clinical trials and drug development programs, as well as a world-renowned center for aging and related diseases.

The University of Texas Health Science Center at San Antonio, also referred to as UT Health San Antonio, is one of the country's leading health sciences universities and is designated as a Hispanic-Serving Institution by the U.S. Department of Education. With missions of teaching, research, patient care and community engagement, its schools of medicine, nursing, dentistry, health professions and graduate biomedical sciences have graduated more than 37,000 alumni who are leading change, advancing their fields, and renewing hope for patients and their families throughout South Texas and the world. To learn about the many ways "We make lives better®," visit http://www.uthscsa.edu.

Stay connected with The University of Texas Health Science Center at San Antonio on Facebook, Twitter, LinkedIn, Instagram and YouTube.

To see how we are battling COVID-19, read inspiring stories on Impact.

Media Contact

Will Sansom, UT Health San Antonio, 210-567-2579, sansom@uthscsa.edu



SOURCE UT Health San Antonio

These press releases may also interest you

at 10:15
The "Technology Breakthroughs and Growth Opportunity in Digital Dentistry" report has been added to ResearchAndMarkets.com's offering. This research service explores the various technology breakthroughs transforming dentistry and the growth...

at 10:14
Verified Market Research recently published a report, "Flow Imaging Microscopy/Dynamic Image Analysis Market" By Type (Biologics, Small Molecules), By Application (Biotechnology Companies, Pharmaceutical Companies), and By Geography. According to...

at 10:13
Results from a new Medisafe survey of more than 4,000 patients reveal new confidence in the COVID-19 vaccine, with 80% of respondents placing trust in the shot, compared to just 13% of patients surveyed in October 2020. The new Medisafe survey aimed...

at 10:11
Amendola Communications, a nationally recognized, award-winning healthcare and technology public relations and marketing firm, announces that virtual care leader eVisit has selected the group to manage its media outreach and thought leadership...

at 10:09
Vynca, a national leader in advance care planning, today announced that the company has finished 2020 with record growth and increased end-of-life planning engagement levels. Propelled by a number of strategic collaborations, Vynca has generated 1.16...

at 10:07
Seelos Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the closing of its previously announced underwritten public...

News published on 27 november 2020 at 18:00 and distributed by: